Back to top

Takeda’s TAK-226 Anemia Trial Offers New Optionality in Hematology

Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clinical study. Takeda (TAK) is running a Phase 2 study called “A Study o...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Takeda Pharmaceutical Co. (TAK)